JNJ/GILD—FDA approves Prezcobix FDC (Prezista + Cobicstat): http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails GILD’s Cobicstat (a constituent of Stribild and Complera) is an alternative to ritonavir for boosting JNJ’s HIV protease inhibitor, Prezista. JNJ will book sales of Prezcobix; the companies haven’t disclosed how much GILD will be paid for the Cobicstat component. Note the parallel to FDA approval of BMY’s Evotaz (#msg-110386161). p.s. Prezcobix would be a superb Scrabble word if it weren’t a brand name.